EBOMAN

EBOMAN – Vaccine manufacture capability

 

The focus of the EBOMAN project is on accelerating the development and manufacturing of a ‘prime- boost’ Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN®-Filo) in development at the Janssen Pharmaceutical Companies of Johnson & Johnson. Ebola vaccines can only be manufactured in facilities with an appropriate biosafety rating. Relatively few manufacturers have the biosafety rating required for the manufacture of Ebola vaccines, and this is slowing down the production of vaccine candidates.

This project will establish a platform capable of rapidly producing sufficient quantities of the vaccine, while adhering to stringent quality and safety requirements. In the short term, this will ensure the delivery of sufficient quantities of the Ad26.ZEBOV and MVA-BN®-Filo vaccine regimen to support the EBOVAC projects to perform the clinical trials. In parallel, this project will create additional vaccine production capacity to allow for the rapid preparation of large quantities of vaccines.

The project duration is from December 2014 until approximately January 2017.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
www.imi.europa.eu
Copyright © 2017 Ebovac | Terms and Conditions | WordPress development by Toast.